Schlieren/Zurich, Switzerland — August 12, 2025 — Leads & Copy — Mabylon AG has raised CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a capital increase and a convertible loan of CHF 15 million, respectively, provided by Mabylon’s existing private investors, with the major investment coming from former management and board members of Roche.
The funding will allow Mabylon to advance MY006, a tri-specific antibody neutralizing peanut allergens, to completion of a Phase Ia/b trial in 2027 with the goal to generate safety and preliminary efficacy data. In addition, the funding will enable Mabylon to further develop its discovery and pre-clinical programs, including MY010, a multi-specific and cross-reactive antibody targeting the birch Bet v 1 allergen, as well as all the major birch-related tree, fruit and nuts allergens. The funding will also support development of MY011, an antibody product for treating grass pollen allergies.
Dr. Thomas Hecht was elected as a new member of Mabylon’s Board of Directors at the shareholders’ assembly, succeeding Prof. Adriano Aguzzi, whose term ended in June 2025.
According to Gottlieb Keller, Chairman of Mabylon’s Board of Directors, the funds will enable Mabylon to reach clinical proof-of-concept and further advance its early-stage pipeline. Alcide Barberis, PhD, CEO of Mabylon, added that the financing validates their approach using human-derived, multi-specific antibodies for the treatment of allergies.
Dr. Ludger Wess / Ines-Regina Buth – info@akampion.com – Tel. +49 40 88 16 59 64 /Tel. +49 30 23 63 27 68
Alcide Barberis, CEO
